[Today's headlines]
Regulations clarify that insurance capital is invested in Hong Kong Stock Connect ETF standards in accordance with Hong Kong Stock Connect stock regulations
Recently, a number of insurance companies received the “Letter on Clarifying the Regulatory Caliber for Investing in Hong Kong Stock Connect ETFs”. The document clearly states that insurance institutions that can invest in Hong Kong Stock Connect shares in accordance with regulatory regulations can start investing in Hong Kong Stock Connect ETFs, which is implemented in accordance with the relevant regulations on the investment of insurance funds into Hong Kong Stock Connect shares. This regulatory framework will be implemented on September 20.
[General outlook]
The Nasdaq China Golden Dragon Index fell 0.67%
Overnight, the Dow Jones Industrial Average fell 161.61 points from the previous trading day, or 0.31%, to close at 51349.98 points; the S&P 500 stock index fell 1.9 points to close at 7704.13 points, or 0.02%; and the Nasdaq Composite Index rose 3.33 points to close at 26939.37 points, or 0.01%.
Major technology stocks had mixed ups and downs, with Meta up 4.50% and Google-A up 1.34%; most storage concept stocks fell, with Micron Technology up 0.81% and SK Hynix down 1.54%; the innovative medicine sector rose by 6.98% and Lilly by 2.68%; lithium stocks generally fell, with US Yabao falling 4.60% and Chile Mining & Chemical falling 2.84%.
Most popular Chinese securities fell, and the Nasdaq China Golden Dragon Index fell 0.67%.
WTI crude oil futures on the New York Mercantile Exchange rose $2.60 for the month to close at $94.76 a barrel, or 2.82%. COMEX gold futures fell $8.30 in the same month, or 0.19%, to $4310.1 per ounce.
[Hot Topics Preview]
China Life Insurance (02628) plans to establish partnerships with China Life Insurance Wuxi Fund, China Life Insurance Chengda and other investors to focus on investing in the two major fields of technological innovation, artificial intelligence and semiconductors
The total amount of capital to be pledged by all partners of the partnership shall not exceed RMB 6 billion, of which the Company intends to pledge no more than RMB 4.5 billion. China Life Insurance Co., Ltd. will act as the manager of the partnership. It is anticipated that the Company will enter into partnership agreements and subsidiary agreements with relevant parties before December 31, 2026.
China Life Insurance: Subsidiary plans to establish partnerships with SDIC Pioneers and other investors to focus on investment in key areas such as Shanghai's three leading industries
The total amount of capital to be pledged by all partners of the partnership is RMB 20 billion, of which the pension insurance company plans to pledge RMB 2 billion. The SDIC pilot will act as the manager of the partnership. The partnership focuses on investing in key areas such as Shanghai's three leading industries (integrated circuits, biomedicine, and artificial intelligence), focusing on undertaking industrial fund shares focusing on major investment strategies and investing in major national strategic projects
Hanson Pharmaceuticals (03692): The marketing license application for injectable Ruikang rivoltamab (HS-20093) to treat osteosarcoma was accepted by the China Drug Administration
The Group's innovative drug HS-20093 (injectable Ruikang rivolutamab) marketing license application was accepted by the China National Drug Administration (NMPA) to treat osteosarcoma patients over the age of 12 who have failed at least previous second-line treatment. HS-20093 for injection is a B7-H3 targeting antibody-drug conjugate (ADC) independently developed by the Group.
Harbin Electric (01133): The motor company and Harbin Electric Group Co., Ltd. signed an equity transfer agreement for Ocean Smart Equipment
After this transfer, Ocean Smart Equipment will become a wholly-owned subsidiary of the motor company. Entering an equity transfer agreement can help the company: lay out the field of deep-sea equipment, accelerate future industrial development, seize opportunities in the underwater drone market, seize opportunities on marine equipment tracks, and add new economic growth points; reinforce marine engineering equipment R&D and manufacturing capabilities, improve the industrial technology system, enhance the enterprise's core strength in the field of marine equipment, and continuously enhance the competitiveness of underwater unmanned products.
Kerry E&C (00683) subsidiary intends to sell the entire issued share capital of Mid-Levels Portfolio (Gladdon) Holdings Limited
The main assets of the target company are all of its interests in the property company. The property is the main asset of a property company. The property includes a top-floor characteristic unit located at 3 Mui Road, Pun Shan, Hong Kong. It has a saleable area of about 1,405 square feet, along with a platform of about 820 square feet above the underground entrance lobby and 14 separate garages.
CSPC Group (01093): Phase III clinical trial of injectable docetaxel (albumin binding) (HB1801) for the treatment of advanced breast cancer officially launched in China
HB1801 is one of the representative drugs independently developed by the Group's nanopharmaceutical technology platform. HB1801 encapsulates docetaxel in human blood albumin. Compared with traditional docetaxel injections, it has significant advantages: (1) safety aspects: no risk of allergic reactions, no hormone pretreatment, can achieve rapid administration at high concentrations, effectively improving drug safety and patient treatment compliance; (2) Efficacy: Many pre-clinical and clinical studies have shown that it has excellent anti-tumor activity. Clinically, larger doses can be administered to further enhance efficacy.
CSPC Group: Phase III clinical trial of JMT101 combined with osidinib for first-line treatment of locally advanced or metastatic non-small cell lung cancer with EGFR20 exon insertion mutation achieved positive topline results
Shiyao Group announced that the Phase III clinical trial developed by the group for first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying the epidermal growth factor receptor (EGFR ex20ins) exon insertion mutation (EGFR ex20ins) reached the main end point in the predetermined mid-term analysis and obtained positive top-line results. JMT101 Compared with platinum plus pemetrexed chemotherapy, this product in combination with osidinib significantly lengthened patients' progression-free survival (PFS) and showed a trend of overall survival (OS) benefits.
Chow Tai Fook Foundations (00659) Announces Annual Results Profit attributable to shareholders increased 11% year over year to HK$2,392.6 billion Final dividend of HK$0.33 per share
The announcement said that in a challenging business environment, the Group's diversified business portfolio showed resilience, driving overall operating profit to increase steadily by 3% year-on-year to HK$4,590.6 billion. The financial services sector achieved strong profit growth and became the Group's largest contributor to operating profit for the first time.
Shandong Gold (01787)'s 2026 production and operation plan is to be adjusted to “36 tons-38 tons of gold production”
The company's 2026 production and operation plan is to be adjusted from the original “no less than 49 tons of gold production” to “36 tons to 38 tons of gold production”.
A major international customer of Hantian Tiancheng (02726) has agreed to purchase additional 6 inch and 8 inch silicon carbide epitaxial wafers
Hantian Tiancheng announced that one of the Group's major international customers (the customer) has agreed to purchase additional 6-inch and 8-inch silicon carbide epitaxial wafers, with a maximum total sales of approximately US$95.8 million, which will be delivered to the customer on or before December 31, 2026 (procurement matters).
Federal Pharmaceuticals (03933) Receives Second Milestone Payment from Novo for UBT251 Exclusive License Agreement
On September 23, 2026, Federal Biotech received US$9 million (after deducting Danish withholding tax) from Novo Pay as a global phase I clinical milestone payment for UBT251 injection for type 2 diabetes. Under an exclusive license agreement and subject to its terms and conditions, Federal Biotech is eligible to receive potential milestone payments of up to $1.8 billion, subject to reaching certain development and sales milestones, as well as tiered sales commissions based on the region's annual net sales.
Shandong Molong (00568) obtained the Abu Dhabi National Petroleum Company oil casing supplier qualification certification
According to Shandong Molong news, on September 24, Shandong Molong successfully passed the Abu Dhabi National Petroleum Company oil casing qualification certification and became a qualified supplier of ADNOC oil casing products.
[Individual stock prices are clear]
Haiguang Xinzheng (01191): 1.6T optical modules began shipping in the second half of the year, and the share of southbound shares rose to 4.2%
Haiguang Core is exhibiting a full-stack self-developed silicon 1.6T optical module and 6.4T NPO at the 27th China International Optoelectronics Fair held from September 9 to 11. Earlier, Hu Yong, the company's deputy general manager and director, said at the mid-term report performance briefing that the company's order guidelines have been filled for the full year of 2027, and 1.6T optical modules will begin to be shipped in the second half of the year to supply leading overseas AI computing power infrastructure customers. R&D and customer verification of 3.2T and 6.4T NPO/CPO are progressing.
Furthermore, Southbound Capital has continued to increase its positions recently, and Haiguangxin has been included in the Hong Kong Stock Connect since September 7 this year. According to the latest data, on September 23, Southbound Capital increased its holdings by 122,700 shares of Haiguang Xinzheng. In the past 5 trading days, Southbound Capital increased its total net holdings by 635,500 shares. Up to now, Southbound Capital holds 3.844,400 shares of Haiguangxin, accounting for 4.19% of the company's issued common shares.